Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

Coronavirus (COVID-19) Resource Center

This guide provides valuable resources for both, Healthcare Professionals (physicians, nurses and practitioners) and Health Consumers about the COVID-19 outbreak and recent research related to this topic.

Below is a list of links related to vaccines, and updated regularly:
 

 

Below is a list of articles related to vaccines, and updated regularly:
 

 

  • Rubin E, et al. "Audio Interview: Waning Immunity against Covid-19." May 26, 2022 N Engl J Med 2022; 386:e64 https://doi.org/10.1056/NEJMe2206981. 
     

  • Accorsi E, et al. "Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron." NEJM May 25, 2022 https://doi.org/10.1056/NEJMc2203165. 
     

  • Goldberg Y, et al. "Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2." NEJM May 25, 2022 https://doi.org/10.1056/NEJMoa2118946. 
     

  • Brown P, et al. "Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults." NEJM May 18, 2022 https://doi.org/10.1056/NEJMc2202879. 
     

  • Evans J, et al. "Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants." NEJM May 18, 2022 https://doi.org/10.1056/NEJMc2205019. 
     

  • Anderson E, et al. "Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age." NEJM May 11, 2022 https://doi.org/10.1056/NEJMoa2203315.  
     

  • Rubin E, et al. "Audio Interview: Do We Need New Covid-19 Vaccines?" May 5, 2022 N Engl J Med 2022; 386:e52 https://doi.org/10.1056/NEJMe2205974. 
     

  • Ten Doesschate T, et al. "Efficacy of Bacillus Calmette-Guerin vaccination against respiratory tract infections in the elderly during the Covid-19 pandemic." Clin Infect Dis. 2022 Mar 5. https://doi.org/10.1093/cid/ciac182. 
     

  • Gray G, et al. "Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa." NEJM May 4, 2022 https://doi.org/10.1056/NEJMc2202061. 
     

  • Nohynek H, et al. "Does the World Still Need New Covid-19 Vaccines?" NEJM May 4, 2022 https://doi.org/10.1056/NEJMe2204695. 
     

  • Hager K, et al. "Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine." NEJM May 4, 2022 https://doi.org/10.1056/NEJMoa2201300. 
     

  • Dai L, et al. "Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults." NEJM May 4, 2022 https://doi.org/10.1056/NEJMoa2202261. 
     

  • Syed AA, et al. "Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review." Immunol Med. 2022 May 1:1-13. https://doi.org/10.1080/25785826.2022.2068331. 
     

  • Noori M, et al. "Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies." Rev Med Virol. 2022 May 1:e2359. https://doi.org/10.1002/rmv.2359. 
     

  • Husby A, et al. "SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents." JAMA Cardiol. 2022 Apr 20. https://doi.org/10.1001/jamacardio.2022.0583. 
     

  • Shi Y, et al. "Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Adolescents, Children, and Infants: A Systematic Review and Meta-Analysis." Front Public Health. 2022 Apr 14;10:829176. https://doi.org/10.3389/fpubh.2022.829176. eCollection 2022. 
     

  • Magen O, et al. "Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting." NEJM April 13, 2022 https://doi.org/10.1056/NEJMoa2201688. 
     

  • Offit P, et al. "Covid-19 Boosters — Where from Here?" NEJM April 13, 2022 https://doi.org/10.1056/NEJMe2203329.

     

  • Casanegra AI, et al. "Risk of venous thromboembolism after COVID-19 vaccination." J Thromb Haemost. 2022 Apr 10. https://doi.org/10.1111/jth.15725. 
     

  • Yoon S, et al. "Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers." NEJM April 6, 2022 https://doi.org/10.1056/NEJMc2201821. 

  • Rubin E, et al. "Audio Interview: Do We Need a Fourth Dose of Covid Vaccine?" April 7, 2022 N Engl J Med 2022; 386:e45 https://doi.org/10.1056/NEJMe2204616. 
     

  • Ramaiah V, et al. "Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India." Lancet. 2022 Apr 2;399(10332):1313-1321. https://doi.org/10.1016/S0140-6736(22)00151-9. (Original study) 

  • Wang YP, et al. "SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis." J Chin Med Assoc. 2022 Apr 1;85(4):421-430. https://doi.org/10.1097/JCMA.0000000000000682. 

  • Rubin E, et al. "Audio Interview: Effectiveness of Covid-19 Vaccination in Children." March 31, 2022 N Engl J Med 2022; 386:e39 https://doi.org/10.1056/NEJMe2204268. 
     

  • Klein N, et al. "Added Benefit of Covid-19 Vaccination after Previous Infection." March 31, 2022 N Engl J Med 2022; 386:1278-1279 https://doi.org/10.1056/NEJMe2201380. 
     

  • Bansal V, et al. "Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: A systematic review, meta-analysis and meta-regression." Aliment Pharmacol Ther. 2022 Mar 30. https://doi.org/10.1111/apt.16913. 
     

  • Dahlqwist E, et al. "Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes." JAMA. 2022 Mar 24. https://doi.org/10.1001/jama.2022.3271. 
     

  • Alton GD, et al. "Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes." JAMA. 2022 Mar 24. https://doi.org/10.1001/jama.2022.4255. 
     

  • Moreira E, et al. "Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine." NEJM March 23, 2022 https://doi.org/10.1056/NEJMoa2200674. 
     

  • Rubin E, et al. "Audio Interview: Can We Make More Effective Covid-19 Vaccines?" March 17, 2022 N Engl J Med 2022; 386:e36 https://doi.org/10.1056/NEJMe2203667. 
     

  • Roel E, et al. "Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis." BMJ. 2022 Mar 16;376:e068373. https://doi.org/10.1136/bmj-2021-068373. 

  • Gonen T, et al. "Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron." NEJM March 16, 2022 https://doi.org/10.1056/NEJMc2202542. 
     
  • Stone RH, et al. "COVID-19 vaccination among pregnant people in the United States: a systematic review." Am J Obstet Gynecol MFM. 2022 Mar 10;4(4):100616. https://doi.org/10.1016/j.ajogmf.2022.100616. 
     
  • Rohban T, et al. "BNT162b2 Vaccine Booster and Covid-19 Mortality." March 10, 2022 N Engl J Med 2022; 386:1000-1001 https://doi.org/10.1056/NEJMc2120044. 
     

  • Liu Q, et al. "Effectiveness and Safety of SARS-CoV-2 Vaccines among Children and Adolescents: A Systematic Review and Meta-Analysis." Vaccines (Basel). 2022 Mar 10;10(3). https://doi.org/10.3390/vaccines10030421. 
     

  • Sablerolles R, et al. "Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming." March 10, 2022 N Engl J Med 2022; 386:951-963 https://doi.org/10.1056/NEJMoa2116747. 
     

  • Rubin E, et al. "Audio Interview: Making Covid-19 Vaccines Available around the World." March 10, 2022 N Engl J Med 2022; 386:e31 https://doi.org/10.1056/NEJMe2203379. 
     

  • Abu-Raddad L, et al. "Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar." NEJM March 9, 2022 https://doi.org/10.1056/NEJMoa2200797. 
     
  • Bachmann M, et al. "The Future of SARS-CoV-2 Vaccination." March 3, 2022 N Engl J Med 2022; 386:899-900 https://doi.org/10.1056/NEJMc2119437. 
     

  • Jones LF, et al. "The Effectiveness of Interventions for Increasing COVID-19 Vaccine Uptake: A Systematic Review." Vaccines (Basel). 2022 Mar 3;10(3). https://doi.org/10.3390/vaccines10030386. 
     

  • Taytard J, et al. "More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age." NEJM March 2, 2022 https://doi.org/10.1056/NEJMc2201556. 
     

  • Andrews N, et al. "Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant." NEJM March 2, 2022 https://doi.org/10.1056/NEJMoa2119451. 
     
  • Hunter D, et al. "Addressing Vaccine Inequity — Covid-19 Vaccines as a Global Public Good." NEJM February 23, 2022 https://doi.org/10.1056/NEJMe2202547. 
     

  • Alunno A, et al. "EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update." Ann Rheum Dis. 2022 Feb 23. https://doi.org/10.1136/annrheumdis-2021-222006. 
     

  • Hamdy NA, et al. "Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis." Vaccines (Basel). 2022 Feb 23;10(3). https://doi.org/10.3390/vaccines10030350. 
     

  • Madhi S, et al. "Population Immunity and Covid-19 Severity with Omicron Variant in South Africa." NEJM February 23, 2022 https://doi.org/10.1056/NEJMoa2119658. 
     

  • Abu-Raddad LJ, et al. "Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression." Lancet. 2022 Feb 21. https://doi.org/10.1016/S0140-6736(22)00152-0. 

  • Ashurov A, et al. "Determining the reliability of rapid SARS-CoV-2 antigen detection in fully vaccinated individuals." J Clin Virol. 2022 Feb 19;148:105119. https://doi.org/10.1016/j.jcv.2022.105119. 
     
  • Hall V, et al. "Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection." NEJM February 16, 2022 https://doi.org/10.1056/NEJMoa2118691. 

  • Hammerman A, et al. "Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19." NEJM February 16, 2022 https://doi.org/10.1056/NEJMoa2119497. 
     

  • Altarawneh H, et al. "Protection against the Omicron Variant from Previous SARS-CoV-2 Infection." NEJM February 9, 2022 https://doi.org/10.1056/NEJMc2200133. 
     

  • Mayr F, et al. "Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans." NEJM February 9, 2022 https://doi.org/10.1056/NEJMc2200415. 
     

  • Sadoff J, et al. "Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S." NEJM February 9, 2022 https://doi.org/10.1056/NEJMoa2117608. 
     

  • Collie S, et al. "Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa." February 3, 2022 N Engl J Med 2022; 386:494-496 https://doi.org/10.1056/NEJMc2119270. 
     

  • Harville T, et al. "Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination." February 2, 2022  https://doi.org/10.1056/NEJMc2119443
     

  • Wang Y, et al. "Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study." Lancet Reg Health West Pac. 2022 Apr;21:100393. https://doi.org/10.1016/j.lanwpc.2022.100393. Epub 2022 Feb 2. 
     

  • Budi DS, et al. "mRNA Covid-19 vaccines in pregnancy: A systematic review." PLoS One. 2022 Feb 2;17(2):e0261350. https://doi.org/10.1371/journal.pone.0261350. eCollection 2022. 
     

  • Bouzas MB, et al. "Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials." Lancet Reg Health Am. 2022 May;9:100196. https://doi.org/10.1016/j.lana.2022.100196. Epub 2022 Feb 2. 
     

  • McConeghy K, et al. "Evaluating the Findings of the IMPACT-C Randomized Clinical Trial to Improve COVID-19 Vaccine Coverage in Skilled Nursing Facilities." JAMA Intern Med. 2022 Jan 31. https://doi.org/10.1001/jamainternmed.2021.8067. 
     

  • Guo X, et al. "Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial." Nat Med. 2022 Feb;28(2):401-409. https://doi.org/10.1038/s41591-021-01677-z. Epub 2022 Jan 27.  

  • Rubin E, et al. "Audio Interview: Addressing the Omicron Variant of SARS-CoV-2." January 27, 2022 N Engl J Med 2022; 386:e16 https://doi.org/10.1056/NEJMe2201214. 
     
  • Andrews N, et al. "Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines." January 27, 2022 N Engl J Med 2022; 386:340-350 https://doi.org/10.1056/NEJMoa2115481. 
     

  • Chemaitelly H, et al. "Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar." NEJM January 26, 2022 https://doi.org/10.1056/NEJMc2119432. 
     

  • Pajon R, et al. "SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination." NEJM January 26, 2022 https://doi.org/10.1056/NEJMc2119912. 
     
  • Atmar R, et al. "Homologous and Heterologous Covid-19 Booster Vaccinations." NEJM January 26, 2022  https://doi.org/10.1056/NEJMoa2116414. 
     

  • Takashita E, et al. "Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant." NEJM January 26, 2022 https://doi.org/10.1056/NEJMc2119407. 
     
  • Zhao X, et al. "Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant." NEJM January 26, 2022 https://doi.org/10.1056/NEJMc2119426. 
     

  • Veroniki AA, et al. "Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials." PLoS One. 2022 Jan 21;17(1):e0260733. https://doi.org/10.1371/journal.pone.0260733. eCollection 2022. 
     

  • Clemens R, et al. "Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study." Lancet. 2022 Jan 21. https://doi.org/10.1016/S0140-6736(22)00094-0. 
     

  • Chemaitelly H, et al. "Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar." NEJM January 19, 2022  https://doi.org/10.1056/NEJMc2117933. 
     

  • Tran TM, et al. "Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine." Biomed Pharmacother. 2022 Jan 19;147:112650. https://doi.org/10.1016/j.biopha.2022.112650. 
     

  • Liu N, et al. "BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age." NEJM January 19, 2022 https://doi.org/10.1056/NEJMc2118775. 
     
  • Sablerolles R, et al. "Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming." NEJM January 19, 2022 https://doi.org/10.1056/NEJMoa2116747. 
     

  • Tobudic S, et al. "Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial." Ann Rheum Dis. 2022 Jan 13. https://doi.org/10.1136/annrheumdis-2021-221558. 

  • Rössler A, et al. "SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons." NEJM January 12, 2022 https://doi.org/10.1056/NEJMc2119236. 
     
  • Lin D, et al. "Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina." NEJM January 12, 2022 https://doi.org/10.1056/NEJMoa2117128. 
     

  • Olson S, et al. "Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents." NEJM January 12, 2022 https://doi.org/10.1056/NEJMoa2117995. 
     

  • Rastmanesh R, et al. "Covid-19 Infections in Vaccinated Health Care Workers." NEJM January 5, 2022 https://doi.org/10.1056/NEJMc2117817. 
     
  • Veiga-Gutierrez R, et al. "Effects of Loigolactobacillus coryniformis K8 CECT 5711 on the Immune Response of Elderly Subjects to COVID-19 Vaccination: A Randomized Controlled Trial." Nutrients. 2022 Jan 5;14(1). https://doi.org/10.3390/nu14010228. 
     

  • Eyre D, et al. "Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants." NEJM January 5, 2022 https://doi.org/10.1056/NEJMoa2116597. 
     

  • Schmidt F, et al. "Plasma Neutralization of the SARS-CoV-2 Omicron Variant." NEJM December 30, 2021 https://doi.org/10.1056/NEJMc2119641.  
     
  • Collie S, et al. "Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa." NEJM December 29, 2021 https://doi.org/10.1056/NEJMc2119270. 
     

  • MacKinnon-Cameron D, et al. "Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial." Lancet. 2022 Jan 15;399(10321):237-248. https://doi.org/10.1016/S0140-6736(21)02753-7. Epub 2021 Dec 23. 
     
  • Lacy J, et al. "VITT and Second Doses of Covid-19 Vaccine." NEJM December 22, 2021 https://doi.org/10.1056/NEJMc2118507. 
     

  • Fosbol E, et al. "SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study." BMJ. 2021 Dec 16;375:e068665. https://doi.org/10.1136/bmj-2021-068665. 
     
  • Foxworth R, et al. "Covid-19 Vaccination in American Indians and Alaska Natives — Lessons from Effective Community Responses." NEJM December 18, 2021 https://doi.org/10.1056/NEJMp2113296. 
     

  • Rubin E, et al. "Audio Interview: How Much Protection Does Prior SARS-CoV-2 Infection Provide?" December 16, 2021 N Engl J Med 2021; 385:e100 https://doi.org/10.1056/NEJMe2119539. 
     

  • Morens D, et al. "Universal Coronavirus Vaccines — An Urgent Need." NEJM December 15, 2021 https://doi.org/10.1056/NEJMp2118468. 
     
  • Lilleri D, et al. "SARS-CoV-2 Infection in Vaccinated Health Care Workers." NEJM December 15, 2021 https://doi.org/10.1056/NEJMc2117119. 
     

  • Chemaitelly H, et al. "Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant." NEJM December 15, 2021 https://doi.org/10.1056/NEJMc2110300. 
     

  • Dunkle L, et al. "Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico." NEJM December 15, 2021 https://doi.org/10.1056/NEJMoa2116185. 
     
  • Chemaitelly H, et al. "Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar." December 9, 2021 N Engl J Med 2021; 385:e83 https://doi.org/10.1056/NEJMoa2114114. 
     

  • Levin E, et al. "Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months." December 9, 2021 N Engl J Med 2021; 385:e84 https://doi.org/10.1056/NEJMoa2114583. 
     
  • Rubin E, et al. "Audio Interview: Waning Immunity against SARS-CoV-2." December 9, 2021 N Engl J Med 2021; 385:e99 https://doi.org/10.1056/NEJMe2119211. 

  • Patel M, et al. "Booster Doses and Prioritizing Lives Saved." NEJM December 8, 2021 https://doi.org/10.1056/NEJMe2117592. 
     
  • Bar-On Y, et al. "Protection against Covid-19 by BNT162b2 Booster across Age Groups." NEJM December 8, 2021 https://doi.org/10.1056/NEJMoa2115926. 
     

  • Arbel R, et al. "BNT162b2 Vaccine Booster and Mortality Due to Covid-19." NEJM December 8, 2021 https://doi.org/10.1056/NEJMoa2115624. 
     
  • McGarry B, et al. "Nursing Home Staff Vaccination and Covid-19 Outcomes." NEJM December 8, 2021 https://doi.org/10.1056/NEJMc2115674. 
     

  • Alunno A, et al. "Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations." Ann Rheum Dis. 2021 Dec 7. https://doi.org/10.1136/annrheumdis-2021-221575. 
     

  • Neoh ZCF, et al. "Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis." Blood Adv. 2022 Apr 12;6(7):2014-2034. https://doi.org/10.1182/bloodadvances.2021006333. 
     

  • Witberg G, et al. "Myocarditis after Covid-19 Vaccination in a Large Health Care Organization." December 2, 2021 N Engl J Med 2021; 385:2132-2139 https://doi.org/10.1056/NEJMoa2110737. 
     

  • Caforio A, et al. "Receipt of mRNA Vaccine against Covid-19 and Myocarditis." December 2, 2021 N Engl J Med 2021; 385:2189-2190 https://doi.org/10.1056/NEJMe2116493. 
     

  • Cornelius V, et al. "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial." Lancet. 2021 Dec 2. https://doi.org/10.1016/S0140-6736(21)02717-3. 
     

  • Sheikh A, et al. "BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant." December 2, 2021 N Engl J Med 2021; 385:2195-2197 https://doi.org/10.1056/NEJMc2113864. 
     
  • Fauver J, et al. "Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons." NEJM December 1, 2021 https://doi.org/10.1056/NEJMc2102507. 
     

  • Rosenberg E, et al. "Covid-19 Vaccine Effectiveness in New York State." NEJM December 1, 2021 https://doi.org/10.1056/NEJMoa2116063. 
     

  • Rubin E, et al. "Covid-19 mRNA Vaccines — Six of One, Half a Dozen of the Other." NEJM December 1, 2021 https://doi.org/10.1056/NEJMe2117446. 
     
  • Dickerman B, et al. "Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans." NEJM December 1, 2021 https://doi.org/10.1056/NEJMoa2115463. 
     

  • Kohler S, et al. "Vaccine-Induced Thrombocytopenia with Severe Headache." November 25, 2021 N Engl J Med 2021; 385:2103-2105 https://doi.org/10.1056/NEJMc2112974. 
     

  • Murphy W, et al. "A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination." NEJM November 24, 2021 https://doi.org/10.1056/NEJMcibr2113694. 
     

  • Ongarj J, et al. "Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population." Vaccines (Basel). 2021 Nov 23;9(12). https://doi.org/10.3390/vaccines9121375. 
     

  • Cosgrove C, et al. "Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial." Lancet Respir Med. 2021 Nov 17. https://doi.org/10.1016/S2213-2600(21)00409-4. 
     

  • Cappel-Porter H, et al. "Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial." Lancet. 2021 Nov 11. https://doi.org/10.1016/S0140-6736(21)02329-1. 
     
  • Monto A, et al. "The Future of SARS-CoV-2 Vaccination — Lessons from Influenza." November 11, 2021 N Engl J Med 2021; 385:1825-1827 https://doi.org/10.1056/NEJMp2113403. 
     

  • Serhani MA, et al. "Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review." Vaccines (Basel). 2021 Nov 10;9(11). https://doi.org/10.3390/vaccines9111305. 
     
  • Torgovnick J, et al. "Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant." NEJM November 10, 2021 https://doi.org/10.1056/NEJMc2113090. 
     

  • Walter E, et al. "Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age." November 9, 2021 https://doi.org/10.1056/NEJMoa2116298. 
     
  • Baden L, et al. "Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase." November 4, 2021 N Engl J Med 2021; 385:1774-1785 https://doi.org/10.1056/NEJMoa2113017. 
     

  • McClymont E, et al. "Systematic review of the safety, immunogenicity, and effectiveness of COVID-19 vaccines in pregnant and lactating individuals and their infants." Int J Gynaecol Obstet. 2021 Nov 4. https://doi.org/10.1002/ijgo.14008. 
     
  • Santacatterina M, et al. "Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines." November 4, 2021 N Engl J Med 2021; 385:1817-1821 https://doi.org/10.1056/NEJMc2113575. 
     
  • Santin A, et al. "VITT after ChAdOx1 nCoV-19 Vaccination." NEJM November 3, 2021 https://doi.org/10.1056/NEJMc2111026. 
     

  • Baden L, et al. "Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge." NEJM November 3, 2021 https://doi.org/10.1056/NEJMc2115597. 
     

  • Tartour E, et al. "Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review." Clin Microbiol Infect. 2021 Oct 28. https://doi.org/10.1016/j.cmi.2021.09.036. 
     

  • Noorchashm H, et al. "Equivalency of Protection From Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis." Cureus. 2021 Oct 28;13(10):e19102. https://doi.org/10.7759/cureus.19102. eCollection 2021 Oct. 
     

  • Dagan N, et al. "Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex." NEJM October 27, 2021 https://doi.org/10.1056/NEJMc2115045. 
     
  • Rubin E, et al. "Audio Interview: A New Look at Covid-19 Vaccine Boosters." October 21, 2021 N Engl J Med 2021; 385:e72 https://doi.org/10.1056/NEJMe2116820. 

  • Magnus M, et al. "Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage." NEJM October 20, 2021 https://doi.org/10.1056/NEJMc2114466. 
     

  • Kulper-Schiek W, et al. "Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021." Euro Surveill. 2021 Oct;26(41). 14 Oct  2021 https://doi.org/10.2807/1560-7917.ES.2021.26.41.2100920. 
     

  • Rubin E, et al. "Audio Interview: Are Covid-19 Vaccine Boosters Necessary?" October 7, 2021 N Engl J Med 2021; 385:e63 https://doi.org/10.1056/NEJMe2115835. 
     

  • Sanders J, et al. "Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines." November 4, 2021 N Engl J Med 2021; 385:1817-1821 https://doi.org/10.1056/NEJMc2113575. 
     

  • Tian YC, et al. "Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease: A Systematic Review and Meta-analysis." JAMA Netw Open. 2021 Oct 1;4(10):e2131749. https://doi.org/10.1001/jamanetworkopen.2021.31749. 
     

  • Falsey A, et al. "Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine." NEJM September 29, 2021 https://doi.org/10.1056/NEJMoa2105290. 
     
  • Shen Q, et al. "Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review." Vaccines (Basel). 2021 Sep 29;9(10). https://doi.org/10.3390/vaccines9101102. 
     

  • Weinreich D, et al. "REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19." NEJM September 29, 2021 https://doi.org/10.1056/NEJMoa2108163. 
     
  • Sikron FH, et al. "Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study." Clin Microbiol Infect. 2021 Sep 27. https://doi.org/10.1016/j.cmi.2021.09.018. 
     

  • Sahly H, et al. "Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase." NEJM September 22, 2021 https://doi.org/10.1056/NEJMoa2113017. 
     

  • Pilishvili T, et al. "Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel." NEJM September 22, 2021 https://doi.org/10.1056/NEJMoa2106599. 
     
  • Gonzalez PA, et al. "Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile." Clin Infect Dis. 2021 Sep 19. https://doi.org/10.1093/cid/ciab823. 
     
  • Yeung WWY, et al. "Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong." Ann Rheum Dis. 2021 Oct 22. https://doi.org/10.1136/annrheumdis-2021-221571. 
     

  • Toscani I, et al. "COVID-19 Vaccines in Cancer Patients. Seropositivity and Safety." Systematic Review and Meta-Analysis. Vaccines (Basel). 2021 Sep 20;9(9). https://doi.org/10.3390/vaccines9091048. 
     

  • Rubin E, et al. "Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters." September 16, 2021 N Engl J Med 2021; 385:e48 https://doi.org/10.1056/NEJMe2115200. 
     
  • Lee G, et al. "The Importance of Context in Covid-19 Vaccine Safety." September 16, 2021 N Engl J Med 2021; 385:1138-1140 https://doi.org/10.1056/NEJMe2112543. 
     
  • Lin C, et al. "BNT162b2 Covid-19 Vaccine in Adolescents." NEJM September 15, 2021 https://doi.org/10.1056/NEJMc2113394. 
     
  • Thomas S, et al. "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months." NEJM September 15, 2021 https://doi.org/10.1056/NEJMoa2110345. 
     
  • Falsey A, et al. "SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3." NEJM September 15, 2021 https://doi.org/10.1056/NEJMc2113468. 
     
  • Salih F, et al. "Vaccine-Induced Thrombocytopenia with Severe Headache." NEJM September 15, 2021 https://doi.org/10.1056/NEJMc2112974. 
     
  • Okhotin A,  "Effectiveness of an Inactivated SARS-CoV-2 Vaccine." NEJM September 15, 2021 https://doi.org/10.1056/NEJMc2112423. 
     
  • Normark J, et al. "Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination." September 9, 2021 N Engl J Med 2021; 385:1049-1051 https://doi.org/10.1056/NEJMc2110716. 
     
  • Ellington S, et al. "On Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons." NEJM September 8, 2021 https://doi.org/10.1056/NEJMc2113516
     
  • Zauche L, et al. "Receipt of mRNA Covid-19 Vaccines and Risk of Spontaneous Abortion." NEJM September 8, 2021 https://doi.org/10.1056/NEJMc2113891
     
  • Thompson M, et al. "Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings." NEJM September 8, 2021 https://doi.org/10.1056/NEJMoa2110362
     
  • Dean N, et al. "Covid-19 Vaccine Effectiveness and the Test-Negative Design." NEJM September 8, 2021 https://doi.org/10.1056/NEJMe2113151
  • Shah A, et al. "Effect of Vaccination on Transmission of SARS-CoV-2." NEJM September 8, 2021 https://doi.org/10.1056/NEJMc2106757
     
  • Hung IF, et al. "Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3." Vaccines (Basel). 2021 Sep 4;9(9). https://doi.org/10.3390/vaccines9090989. 

  • Keehner J, et al. "Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce." NEJM September 1, 2021 https://doi.org/10.1056/NEJMc2112981. 
     
  • Deepak P, et al. "Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis." Autoimmun Rev. 2021 Aug 30:102927. https://doi.org/10.1016/j.autrev.2021.102927. 
     
  • Uzun G, et al. "No Correlation between Anti-PF4 and Anti–SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination." August 25, 2021 NEJM https://doi.org/10.1056/NEJMc2111305. 
     
  • Lee G, et al. "The Importance of Context in Covid-19 Vaccine Safety." NEJM August 25, 2021 https://doi.org/10.1056/NEJMe2112543
     
  • Mei XW, et al. "Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study." BMJ. 2021 Aug 26;374:n1931. https://doi.org/10.1136/bmj.n1931. 
  • Barda N, et al. "Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting." NEJM August 25, 2021 https://doi.org/10.1056/NEJMoa2110475. 
     
  • Chen Y, et al. "Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials." Vaccines (Basel). 2021 Aug 23;9(8). https://doi.org/10.3390/vaccines9080939. 
     
  • Harris R, et al. "Effect of Vaccination on Household Transmission of SARS-CoV-2 in England." August 19, 2021 N Engl J Med 2021; 385:759-760 https://doi.org/10.1056/NEJMc2107717. 
     
  • Verma A, et al. "Myocarditis after Covid-19 mRNA Vaccination." NEJM August 18, 2021 https://doi.org/10.1056/NEJMc2109975. 
     
  • Young B, et al. "Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors." NEJM August 18, 2021 https://doi.org/10.1056/NEJMoa2108453. 
     
  • Lange B, et al. "Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers." NEJM August 18, 2021 https://doi.org/10.1056/NEJMc2108076. 
     
  • Sun J, et al. "Efficacy and Safety of Corticosteroid Use in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis." Infect Dis Ther. 2021 Aug 13.  https://doi.org/10.1007/s40121-021-00518-3. 
     
  • Andrews N, et al. "Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant." August 12, 2021 N Engl J Med 2021; 385:585-594 https://doi.org/10.1056/NEJMoa2108891. 
     
  • Berman G, et al. "Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents." NEJM August 11, 2021 https://doi.org/10.1056/NEJMoa2109522. 
     
  • Stuart ASV, et al. "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial." Lancet. 2021 Aug 6. https://doi.org/10.1016/S0140-6736(21)01694-9. 

  • Pavord S, et al. "Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis." NEJM August 11, 2021 https://doi.org/10.1056/NEJMoa2109908. 
     
  • Hall V, et al. "Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients." NEJM August 11, 2021 https://doi.org/10.1056/NEJMc2111462. 
     
  • Williams W, et al. "Third Time’s a Charm — Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients." NEJM August 11, 2021 https://doi.org/10.1056/NEJMe2112866. 
     
  • Bergwerk M, et al. "Covid-19 Breakthrough Infections in Vaccinated Health Care Workers." NEJM July 28, 2021 https://doi.org/10.1056/NEJMoa2109072. 
     
  • Chen X, et al. "Evaluation of the safety profile of COVID-19 vaccines: a rapid review.BMC Med. 2021 Jul 28;19(1):173. https://doi.org/10.1186/s12916-021-02059-5. 

  • Evans S, et al. "Vaccine Effectiveness Studies in the Field." July 21, 2021 NEJM https://doi.org/10.1056/NEJMe2110605. 
     
  • Bernal J, et al. "Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant." July 21, 2021 NEJM https://doi.org/10.1056/NEJMoa2108891. 
     
  • Struyf F, et al. "ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant." NEJM July 21, 2021 https://doi.org/10.1056/NEJMc2110093. 
     
  • Yousaf A, et al. "Household Transmission of SARS-CoV-2 from Children and Adolescents." July 21, 2021 NEJM https://doi.org/10.1056/NEJMc2031915. 
     
  • Vygen-Bonnet S, et al. "Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021." Euro Surveill. 2021 Jul;26(28). https://doi.org/10.2807/1560-7917.ES.2021.26.28.2100563. 
     
  • Luo J, et al. "Safety and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis." J Med Virol. 2021 Jul 15. https://doi.org/10.1002/jmv.27203. 
  • Gebre M, et al. "Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination." NEJM July 14, 2021 https://doi.org/10.1056/NEJMc2108829. 
     
  • Akova M, et al. "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey." Lancet. 2021 Jul 17;398(10296):213-222. https://doi.org/10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8. 
     
  • Krause P, et al. "SARS-CoV-2 Variants and Vaccines." July 8, 2021 N Engl J Med 2021; 385:179-186 https://doi.org/10.1056/NEJMsr2105280. 
     
  • Rubin E, et al. "Audio Interview: How Well Are Covid-19 Vaccines Working?" July 8, 2021 N Engl J Med 2021; 385:e15 https://doi.org/10.1056/NEJMe2111369. 
     
  • Quinn S, et al. "Addressing Vaccine Hesitancy in BIPOC Communities — Toward Trustworthiness, Partnership, and Reciprocity." July 8, 2021 N Engl J Med 2021; 385:97-100 https://doi.org/10.1056/NEJMp2103104. 

  • Peterson M, et al. "Breakthrough SARS-CoV-2 Infections in Prison after Vaccination." July 7, 2021 NEJM https://doi.org/10.1056/NEJMc2108479. 
     
  • Pinsky B, et al. "Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants." July 7, 2021 NEJM https://doi.org/10.1056/NEJMc2107799. 
  • Jara A, et al. "Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile." July 7, 2021 NEJM https://doi.org/10.1056/NEJMoa2107715. 
     
  • Fan VS, et al. "Age differences in the association of comorbid burden with adverse outcomes in SARS-CoV-2." BMC Geriatr. 2021 Jul 6;21(1):415. https://doi.org/10.1186/s12877-021-02340-5. 
     
  • Selby R, et al. "Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia." July 7, 2021 NEJM https://doi.org/10.1056/NEJMc2109465. 
     
  • Baxter DN, et al. "Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine." N Engl J Med. 2021 Jun 30. https://doi.org/10.1056/NEJMoa2107659. 
     
  • Li C, et al. "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial." Lancet Infect Dis. 2021 Jun 28. https://doi.org/10.1016/S1473-3099(21)00319-4. 
     
  • Shaker M, et al. "The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-analysis, GRADE Assessment, and International Consensus Approach." J Allergy Clin Immunol Pract. 2021 Jun 18. pii: S2213-2198(21)00671-1. https://doi.org/10.1016/j.jaip.2021.06.006. 

  • Riley L, et al. "mRNA Covid-19 Vaccines in Pregnant Women." June 17, 2021 N Engl J Med 2021; 384:2342-2343 https://doi.org/10.1056/NEJMe2107070. 
     
  • Lai K, et al. "Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination." JAMA June 16, 2021 https://doi.org/10.1056/NEJMc2107227. 
     
  • Hacisuleyman E, et al. "Vaccine Breakthrough Infections with SARS-CoV-2 Variants." June 10, 2021 N Engl J Med 2021; 384:2212-2218 https://doi.org/10.1056/NEJMoa2105000. 
     
  • Rubin E, et al. "Audio Interview: Treating Complications of Covid Vaccination." June 10, 2021 N Engl J Med 2021; 384:e107 https://doi.org/10.1056/NEJMe2109757. 
     
  • O’Connell S, et al. "Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19." June 10, 2021 N Engl J Med 2021; 384:2259-2261 https://doi.org/10.1056/NEJMc2103916. 
     
  • Heininger U, et al. "Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19." NEJM June 9, 2021 https://doi.org/10.1056/NEJMc2107809. 
     
  • Bourguignon A, et al. "Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia." NEJM June 9, 2021 https://doi.org/10.1056/NEJMoa2107051. 

  • Blumenthal K, et al. "Delayed Large Local Reactions to mRNA Covid-19 Vaccines in Blacks, Indigenous Persons, and People of Color." NEJM June 9, 2021 https://doi.org/10.1056/NEJMc2108620
     
  • Becker S, et al. "Identifying and Tracking SARS-CoV-2 Variants — A Challenge and an Opportunity." NEJM June 9, 2021 https://doi.org/10.1056/NEJMp2103859. 

  • Greinacher A, et al. "Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination." June 3, 2021 N Engl J Med 2021; 384:2092-2101 https://doi.org/10.1056/NEJMoa2104840. 
     
  • Makhado Z, et al. "Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351) 3 Citing Articles." June 3, 2021 N Engl J Med 2021; 384:2161-2163 https://doi.org/10.1056/NEJMc2104192. 
     
  • Nixon D, et al. "Vaccine Breakthrough Infections with SARS-CoV-2 Variants." NEJM June 2, 2021 https://doi.org/10.1056/NEJMc2107808. 
     
  • Takuva S, et al. "Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study." NEJM June 2, 2021 https://doi.org/10.1056/NEJMc2107920. 
     
  • Luo W, et al. "Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis." Vaccines (Basel). 2021 Jun 1;9(6). https://doi.org/10.3390/vaccines9060582. 
  • Chen Y, et al. "Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac." The Lancet Published:May 27, 2021 https://doi.org/10.1016/S1473-3099(21)00287-5. 
     
  • Kitchin N, et al. "Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents." N Engl J Med. 2021 May 27. https://doi.org/10.1056/NEJMoa2107456. 

  • Volpp K, et al. "Incentives for Immunity — Strategies for Increasing Covid-19 Vaccine Uptake." NEJM May 26, 2021 https://doi.org/10.1056/NEJMp2107719. 
     
  • Xia S, et al. "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial." JAMA. 2021 May 26. https://doi.org/10.1001/jama.2021.8565. 

  • Bhikha S, et al. "Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant." May 20, 2021 N Engl J Med 2021; 384:1899-1909 https://doi.org/10.1056/NEJMoa2103055. 
     
  • White E, et al. "Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents." NEJM May 19, 2021 https://doi.org/10.1056/NEJMc2104849. 

  • Abdool Karim S, et al. "New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications." May 13, 2021 N Engl J Med 2021; 384:1866-1868 https://doi.org/10.1056/NEJMc2100362. 
     
  • Shaw R, et al. "Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data." The Lancet Published May 12, 2021 https://doi.org/10.1016/S0140-6736(21)01115-6. 

  • Leidner D, et al. "Covid-19 Vaccine Acceptance in California State Prisons." NEJM May 12, 2021 https://doi.org/10.1056/NEJMc2105282. 
     
  • Keehner J, et al. "More on SARS-CoV-2 Infection after Vaccination in Health Care Workers." NEJM May 12, 2021 https://doi.org/ 10.1056/NEJMc2106004. 
     
  • Ghorbani S, et al. "Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines (Basel)." 2021 May 6;9(5). https://doi.org/10.3390/vaccines9050467. 

  • Chemaitelly H, et al. "Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants." NEJM May 5, 2021 https://doi.org/10.1056/NEJMc2104974. 
     
  • Leentjens J, et al. "COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year." The Lancet Hematology Published:April 27, 2021 https://doi.org/10.1016/S2352-3026(21)00105-8. 

  • Vandebosch A, et al. "Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19." N Engl J Med. 2021 Apr 21. https://doi.org/10.1056/NEJMoa2101544. 
     
  • Shimabukuro T, et al. "Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons." NEJM April 21, 2021 DOI: 10.1056/NEJMoa2104983. 
     
  • Baeck M, et al. "Delayed Large Local Reactions to mRNA Vaccines." NEJM April 21, 2021 https://doi.org/10.1056/NEJMc2104751. 
     
  • Hacisuleyman E, et al. "Vaccine Breakthrough Infections with SARS-CoV-2 Variants." NEJM April 21, 2021 https://doi.org/10.1056/NEJMoa2105000. 

  • Cines D, et al. "SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia." NEJM April 16, 2021 https://doi.org/10.1056/NEJMe2106315. 
     
  • Scully M, et al. "Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination." NEJM April 16, 2021 https://doi.org/10.1056/NEJMoa2105385. 
     
  • Goel R, et al. "Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination." Science Immunology  15 Apr 2021: Vol. 6, Issue 58, eabi6950 https://doi.org/10.1126/sciimmunol.abi6950. 

  • Kallam A, et al. "Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination." NEJM April 14, 2021 https://doi.org/10.1056/NEJMc2105869. 
     
  • Yang F, et al. "Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues." Science  12 Apr 2021: eabf6648 https://doi.org/10.1126/science.abf6648. 
     
  • Greinacher A, et al. "Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination." NEJM April 9, 2021 https://doi.org/10.1056/NEJMoa2104840. 
     
  • Mahase E, et al. "AstraZeneca vaccine: Blood clots are “extremely rare” and benefits outweigh risks, regulators conclude." BMJ 2021; 373 doi: https://doi.org/10.1136/bmj.n931 (Published 08 April 2021). 
     
  • Krammer F, et al. "Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine." April 8, 2021 N Engl J Med 2021; 384:1372-1374 https://doi.org/10.1056/NEJMc2101667. 
     
  • Katz I, et al. "From Vaccine Nationalism to Vaccine Equity — Finding a Path Forward." April 8, 2021 N Engl J Med 2021; 384:1281-1283 https://doi.org/10.1056/NEJMp2103614. 
     
  • Lustig Y, et al. "Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2." NEJM April 7, 2021 https://doi.org/10.1056/NEJMc2104036. 
     
  • Makowski M, et al. "Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19." NEJM April 6, 2021 https://doi.org/10.1056/NEJMc2103916
     
  • Coppola A, et al. "Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials."  Vaccines (Basel). 2021 Apr 1;9(4). pii: vaccines9040341. https://doi.org/10.3390/vaccines9040341. 

  • Quinn S, et al. "Addressing Vaccine Hesitancy in BIPOC Communities — Toward Trustworthiness, Partnership, and Reciprocity." NEJM March 31, 2021 https://doi.org/10.1056/NEJMp2103104. 
     
  • Nachega J, et al. "Scaling Up Covid-19 Vaccination in Africa — Lessons from the HIV Pandemic." NEJM March 31, 2021 https://doi.org/10.1056/NEJMp2103313. 
     
  • Keehner J, et al. "SARS-CoV-2 Infection after Vaccination in Health Care Workers in California." NEJM March 23, 2021 https://doi.org/10.1056/NEJMc2101927. 
     
  • Nivet M, et al. "Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center." NEJM March 23, 2021 https://doi.org/10.1056/NEJMc2102153. 
     
  • Benenson S, et al. "BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers." NEJM March 23, 2021 https://doi.org/10.1056/NEJMc2101951. 

  • Bradley T, et al. "Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine." NEJM March 23, 2021 https://doi.org/10.1056/NEJMc2102051. 
     
  • Desmond A, et al. "On the Shoulders of Giants — From Jenner’s Cowpox to mRNA Covid Vaccines." NEJM March 20, 2021 https://doi.org/10.1056/NEJMp2034334. 

  • Rubin E, et al. "Audio Interview: Efficacy of Current Covid-19 Vaccines against Variant Viruses." March 18, 2021 N Engl J Med 2021; 384:e53 https://doi.org/10.1056/NEJMe2104584. 
     
  • Madhi S, et al. "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant." NEJM March 16, 2021 https://doi.org/10.1056/NEJMoa2102214. 
     
  • Altmann D, et al. "Immunity to SARS-CoV-2 variants of concern." Science  12 Mar 2021: Vol. 371, Issue 6534, pp. 1103-1104 https://doi.org/10.1126/science.abg7404. 

  • Goralnick E, et al. "Mass-Vaccination Sites — An Essential Innovation to Curb the Covid-19 Pandemic." NEJM March 10, 2021 https://doi.org/10.1056/NEJMp2102535. 
     
  • Estcourt L, et al. "Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial." medRxiv 2021.03.09.21252736; https://doi.org/10.1101/2021.03.09.21252736. 
     
  • Liu Y, et al. "Neutralizing Activity of BNT162b2-Elicited Serum." NEJM March 8, 2021 https://doi.org/10.1056/NEJMc2102017. 
     
  • Kadire S, et al. "Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination." March 4, 2021 N Engl J Med 2021; 384:e28 https://doi.org/10.1056/NEJMclde2101987. 
     
  • Blumenthal K, et al. "Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2." NEJM March 3, 2021 https://doi.org/10.1056/NEJMc2102131. 
     
  • Kramer D, et al. "Choices in a Crisis — Individual Preferences among SARS-CoV-2 Vaccines." NEJM March 3, 2021 https://doi.org/10.1056/NEJMp2102146. 
     
  • Blendon R, et al. "An Uncertain Public — Encouraging Acceptance of Covid-19 Vaccines." NEJM March 3, 2021 https://doi.org/10.1056/NEJMp2100351. 
     
  • Walker S, et al. "SARS-CoV-2 Vaccines." JAMA. 2021;325(13):1318-1320. https://doi.org/10.1001/jama.2021.3199 February 26, 2021. 
     
  • Lee T, et al. "Last-Mile Logistics of Covid Vaccination — The Role of Health Care Organizations." NEJM February 25, 2021 N Engl J Med 2021; 384:685-687 https://doi.org/10.1056/NEJMp2100574. 
     
  • Rubin E, et al. "Audio Interview: The Real-World Effectiveness of Covid-19 Vaccination." February 25, 2021 N Engl J Med 2021; 384:e40 https://doi.org/10.1056/NEJMe2103272. 
     
  • Dagan N, et al. "BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting." NEJM February 24, 2021 https://doi.org/10.1056/NEJMoa2101765. 
     
  • Kreiss Y, et al. "Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients." The Lancet February 18, 2021 https://doi.org/10.1016/S0140-6736(21)00448-7. 
     
  • Kojima N, et al. "The Covid-19 Vaccine-Development Multiverse." February 18, 2021 N Engl J Med 2021; 384:681-682. https://doi.org/10.1056/NEJMc2034838. 
     
  • Klass P, et al. "Vaccinating Children against Covid-19 — The Lessons of Measles" February 18, 2021 N Engl J Med 2021; 384:589-591 https://doi.org/10.1056/NEJMp2034765. 
     
  • Koch M, et al. "Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report." NEJM February 17, 2021 https://doi.org/10.1056/NEJMc2102179. 
     
  • Rosenbaum L, et al. "Escaping Catch-22 — Overcoming Covid Vaccine Hesitancy." NEJM February 12, 2021 DOI: 10.1056/NEJMms2101220. 
     
  • Ribas A, et al. "Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited." Cancer Discovery 11.2 (2021): 233-236. Web. 24 Mar. 2021.  https://doi.org/10.1158/2159-8290.CD-20-1817 Published February 2021. 
     
  • Shimabukuro T, et al. "Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021." JAMA. Published online February 12, 2021. https://doi.org/10.1001/jama.2021.1967. 
     
  • Kachalia A, et al. "Who Goes First? Government Leaders and Prioritization of SARS-CoV-2 Vaccines." February 4, 2021 N Engl J Med 2021; 384:e15 https://doi.org/10.1056/NEJMpv2036128. 
     
  • Schenkelberg T, et al. "Development and deployment of COVID-19 vaccines for those most vulnerable." Science Translational Medicine  03 Feb 2021: Vol. 13, Issue 579, eabd1525 https://doi.org/10.1126/scitranslmed.abd1525. 
     
  • Shcheblyakov DV, et al. "Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia." Lancet. 2021 Feb 2. pii: S0140-6736(21)00234-8. https://doi.org/10.1016/S0140-6736(21)00234-8. 
     
  • Beayni N, et al. "Available COVID-19 vaccine platforms: A roadmap to eclipsing the SARS-CoV-2 viral saga." Accepted 19-01-2021 The Internati onal Arabic Journal of Anti microbial Agents Vol. 11 No. 1:2 https://doi.org/10.3823/853. 
     
  • Placebo-Controlled Trials of Covid-19 Vaccines — Why We Still Need Them.” January 14, 2021 N Engl J Med 2021; 384:e2 https://doi.org/10.1056/NEJMp2033538. 
     
  • Kimmel M., et al. “Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine.” JAMA January 13, 2021. https://doi.org/10.1056/NEJMoa2034201. 
     
  • Doshi P, et al. "Peter Doshi: Pfizer and Moderna’s “95% effective vaccines—we need more details and the raw data" January 4, 2021. 
     
  • Castells MC, et al. “Maintaining Safety with SARS-CoV-2 Vaccines.” N Engl J Med. 2020 Dec 30;NEJMra2035343. https://doi.org/10.1056/NEJMra2035343. Online ahead of print. 
     
  • Essink B, et al. "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine." N Engl J Med. 2020 Dec 30. https://doi.org/10.1056/NEJMoa2035389. 
     
  • Anderson Evan, et al. "Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults." December 17, 2020. N Engl J Med 2020; 383:2427-2438. https://doi.org/10.1056/NEJMoa2028436. 
     
  • D. F., et al. "Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials." BMJ Yale December 14, 2020. https:doi.org/10.1101/2020.12.14.20248137. 
     
  • Polack Fernando, et al. "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine." NEJM December 10, 2020. https://doi.org/10.1056/NEJMoa2034577. 
     
  • Madhi SA, et al. "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK." Lancet. 2020 Dec 8. pii: S0140-6736(20)32661-1. https://doi.org/10.1016/S0140-6736(20)32661-1. 
     
  • Haynes B, et al. "Prospects for a safe COVID-19 vaccine." Science Translational Medicine  04 Nov 2020: Vol. 12, Issue 568, eabe0948 https://doi.org/10.1126/scitranslmed.abe0948. 
     
  • Cimolai N, et al. "Do RNA vaccines obviate the need for genotoxicity studies?" Mutagenesis, Volume 35, Issue 6, November 2020, Pages 509–510, https://doi.org/10.1093/mutage/geaa028. 
     
  • Susanne H Hodgson, et al. “What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.” Lancet Infect Dis . 2020 Oct 27; https://doi.org/10.1016/S1473-3099(20)30773-8. 
     
  • Doshi P, et al. "Will covid-19 vaccines save lives? Current trials aren’t designed to tell us." BMJ 2020; 371  https://doi.org/10.1136/bmj.m4037 (Published 21 October 2020). 
     
  • Ping Li, et al. "Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates." NEJM . October 14, 2020 https://doi.org/10.1056/NEJMoa2027906 . 
     
  • Archana Koirala, et al. “Vaccines for COVID-19: The current state of play.” Paediatric Respiratory Reviews Volume 35, September 2020, Pages 43-49. https://doi.org/10.1016/j.prrv.2020.06.010. 
     
  • Denis Y Logunov, et al. “Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2studies from Russia.” Lancet 2020, 396: 887-97. 26 September – 2 October 2020. 
     
  • Keech Cheryl, et al. "Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine". NEJM September 2, 2020. https://doi.org/10.1056/NEJMoa2026920. 
     
  • Jian-Ying Huang, et al. “Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.” The Lancet Volume 396, Issue 10249, 15–21 August 2020, Pages 479-488. https://doi.org/10.1016/S0140-6736(20)31605-6 . 
     
  • Kizzmekia S. Corbett, et al. "Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates." NEJM July 28, 2020. https://doi.org/10.1056/NEJMoa2024671. 

  • Zhu Feng-Cai, et al. “Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.” Lancet. 2020 Jun 13;395(10240):1845-1854. https://doi.org/10.1016/S0140-6736(20)31208-3. Epub 2020 May 22. 

 

 

As part of K2P COVID-19 Series, K2P center is pleased to launch the latest product: “A Closer Look at COVID-19 Vaccines: The Known, the Unknown, and the Uncertain”. (Arabic Version) , (English Version) , (Full Product Version)

 This is the second product on the COVID-19 Vaccine developed by K2P. To know more about the first product, you can check at: Countdown to a COVID-19 Vaccine: Spotlight on Lebanon

 

Images